Clearside Biomedical Inc (CLSD) - Net Assets
Based on the latest financial reports, Clearside Biomedical Inc (CLSD) has net assets worth $-53.95 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.64 Million) and total liabilities ($65.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Clearside Biomedical Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-53.95 Million |
| % of Total Assets | -463.45% |
| Annual Growth Rate | N/A |
| 5-Year Change | -543.4% |
| 10-Year Change | N/A |
| Growth Volatility | 1520.77 |
Clearside Biomedical Inc - Net Assets Trend (2012–2024)
This chart illustrates how Clearside Biomedical Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Clearside Biomedical Inc for the complete picture of this company's asset base.
Annual Net Assets for Clearside Biomedical Inc (2012–2024)
The table below shows the annual net assets of Clearside Biomedical Inc from 2012 to 2024. For live valuation and market cap data, see market cap of Clearside Biomedical Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-38.85 Million | -144.19% |
| 2023-12-31 | $-15.91 Million | -250.01% |
| 2022-12-31 | $10.61 Million | -72.07% |
| 2021-12-31 | $37.98 Million | +333.36% |
| 2020-12-31 | $8.76 Million | -21.46% |
| 2019-12-31 | $11.16 Million | -52.76% |
| 2018-12-31 | $23.62 Million | +10.30% |
| 2017-12-31 | $21.41 Million | -70.12% |
| 2016-12-31 | $71.66 Million | +295.47% |
| 2015-12-31 | $-36.66 Million | -90.80% |
| 2014-12-31 | $-19.21 Million | -78.93% |
| 2013-12-31 | $-10.74 Million | -4592.89% |
| 2012-12-31 | $239.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Clearside Biomedical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35099400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $77.00K | % |
| Other Components | $316.34 Million | % |
| Total Equity | $-38.85 Million | 100.00% |
Clearside Biomedical Inc Competitors by Market Cap
The table below lists competitors of Clearside Biomedical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Qlucore AB
ST:QCORE
|
$2.15 Million |
|
Treatt PLC
LSE:TET
|
$2.15 Million |
|
Bohra Industries Limited
NSE:BOHRAIND
|
$2.15 Million |
|
Ace Integrated Solutions Limited
NSE:ACEINTEG
|
$2.15 Million |
|
Direct Digital Holdings Inc
NASDAQ:DRCT
|
$2.14 Million |
|
Afentra PLC
LSE:AET
|
$2.14 Million |
|
British Smaller Companies Vct 2 Plc
LSE:BSC
|
$2.14 Million |
|
Moab Minerals Ltd
AU:MOM
|
$2.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Clearside Biomedical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -15,912,000 to -38,855,000, a change of -22,943,000.
- Net loss of 34,352,000 reduced equity.
- New share issuances of 16,389,000 increased equity.
- Other factors decreased equity by 4,980,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-34.35 Million | -88.41% |
| Share Issuances | $16.39 Million | +42.18% |
| Other Changes | $-4.98 Million | -12.82% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Clearside Biomedical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.04 | $0.41 | x |
| 2013-12-31 | $-107.21 | $0.41 | x |
| 2014-12-31 | $-23.48 | $0.41 | x |
| 2015-12-31 | $-44.80 | $0.41 | x |
| 2016-12-31 | $5.47 | $0.41 | x |
| 2017-12-31 | $12.69 | $0.41 | x |
| 2018-12-31 | $11.53 | $0.41 | x |
| 2019-12-31 | $4.38 | $0.41 | x |
| 2020-12-31 | $2.83 | $0.41 | x |
| 2021-12-31 | $9.51 | $0.41 | x |
| 2022-12-31 | $2.64 | $0.41 | x |
| 2023-12-31 | $-3.86 | $0.41 | x |
| 2024-12-31 | $-7.90 | $0.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Clearside Biomedical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2064.42%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-238.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -1644.77% | 0.00% | 0.00x | 3.97x | $-3.95 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.18 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.27 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.97 Million |
| 2016 | -36.12% | -4977.31% | 0.01x | 1.18x | $-33.05 Million |
| 2017 | -275.39% | -17094.20% | 0.01x | 1.89x | $-61.12 Million |
| 2018 | -350.63% | -276060.00% | 0.00x | 1.87x | $-85.18 Million |
| 2019 | -273.90% | -1406.30% | 0.08x | 2.40x | $-31.67 Million |
| 2020 | -205.75% | -228.40% | 0.41x | 2.20x | $-18.91 Million |
| 2021 | 0.99% | 1.27% | 0.69x | 1.13x | $-3.42 Million |
| 2022 | -310.62% | -2482.82% | 0.03x | 4.84x | $-34.01 Million |
| 2023 | 0.00% | -394.91% | 0.24x | 0.00x | $-30.89 Million |
| 2024 | 0.00% | -2064.42% | 0.07x | 0.00x | $-30.47 Million |
Industry Comparison
This section compares Clearside Biomedical Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Clearside Biomedical Inc (CLSD) | $-53.95 Million | -1644.77% | N/A | $2.15 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more